Singapore still falling short for home-grown biotechs seeking IPO

Tough SGX mainboard listing rules, low liquidity, lack of deep institutional investor pool and sparse research ecosystem among reasons cited


HOME-GROWN biotech companies would rather look for opportunities further ashore than list on the Singapore Exchange (SGX). Although the city-state has a growing biotech ecosystem, the local bourse has not been able to benefit much from it.

Industry players who spoke to